Abstract
The presence of immunoreactive prostate-specific antigen (IR-PSA) has been reported in breast cancers and has been suggested to confer a positive prognosis. However, recent large, well-controlled studies have found no significant prognostic value when IR-PSA positivity is examined as an independent variable, even when ultrasensitive immunofluorometric techniques are utilized. The present study, using indirect immunohistochemistry on 75 formalin-fixed, paraffin-embedded breast cancers shows PSA immunoreactivity in only seven of 75 cases (9%), suggesting that PSA positivity in breast carcinoma is not useful as a prognostic or tumor marker with hospital-based methods.
Similar content being viewed by others
References
Alanen KA, Kuopio T, Collan YU, Kronqvist P, Juntti L, Nevalainen TJ: Immunohistochemical labelling for prostatespecific antigen in breast carcinomas. Breast Cancer Res Treat 56: 169-176, 1999
Levesque MA, Hu H, D'Costa M, Diamandis EP: Prostatespecific antigen expression by various tumors. J Clin Lab Anal 9: 123-128, 1995
Kucera E, Kainz C, Tempfer C, Ziellinger R, Koelbl H, Sluitz G: Prostate specific antigen (PSA) in breast and ovarian cancer. Anticancer Res 17: 4735-4738, 1997
Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M, Croce CM: Prostatespecific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171-178, 1996
Ferguson RA, Yu H, Kalyvas M, Zammit, Diamandis EP: Ultrasensitive detection of prostate-specific antigen by a timeresolved immunofluorometric assay and the Immulite®immunochemiluminescent third-generation assay: potential applications in prostate and breast cancers. Clin Chem 42: 675-684, 1996
Diamandis EP, Yu H, Lopez-Otin C: Prostate specific antigen: A new constituent of breast cyst fluid. Breast Cancer Res Treat 38: 259-264, 1996
YuH, Diamandis EP: Protease prostate specific antigen in milk of lactating women. Clin Chem 41: 54-60, 1995
Diamandis EP, Yu H, Sutherland DJA: Detection of prostatespecific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32: 301-310, 1994
Monne M, Croce CM, Yu H, Diamandis EP: Molecular characterization of prostate-specific antigen messenger RNA expressed in breast tumors. Cancer Res 54(24): 6344-6347, 1994
Cohen P, Graves HCB, Peehl DM, Kamarci M, Giundicde LC, Rosenfeld RG: Prostate-specific antigen (PSA) is an insulinlike growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053, 1992
Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factorbinding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77: 229-233, 1993
Yu H, Levesque MA, Khosravi MJ, Papanastasiou-Diamandi A, Clark GM, Diamandis EP: Associations between insulinlike growth factors and their binding proteins and other prognostic indicators in breast cancer. Br J Cancer 74(8): 1242-1247, 1996
Yu H, Diamandis EP, Zarghami N, Grass L: Induction of prostate-specific antigen production by steroids and tamoxifen in breast cancer cell lines. Breast Cancer Res Treat 32: 291-300, 1994
Zarghami N, Grass L, Diamandis EP: Steroid hormone regulation of prostate-specific antigen gene expression in breast cancer. Br J Cancer 75(4): 579-588, 1997
Yu H, Diamandis EP, Monne M, Croce CM: Oral contraceptive-induced expression of prostate-specific antigen in the female breast. J Biol Chem 270: 6615-6618, 1995
Diamandis EP, Helle SI, Yu H, Melegos DN, Lundgren S, Lonning P: Prognostic value of plasma prostate specific antigen after megestrol acetate treatment in patients with metastatic breast carcinoma. Cancer 85(4): 891-898, 1999
Romppanen J, Keskikuru R, Kataja V, Eskelinen M, Kosma V-M, Savolainen K, Uusitupa M, Mononen I: Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women. Br J Cancer 79: 1583-1587, 1999
Hautmann S, Huland E, Grupp C, Haese A, Huland H: Supersensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer. Anticancer Res 20(3B): 2151-2154, 2000
Foekens JA, Diamandis EP, Yu H, Look MP, Meijer-van Gelder ME, WLJ van Putten, Klijn JGM: Expression of prostate-specific antigen (PSA) correlates with poor response to tamoxifen therapy in recurrent breast cancer. Br J Cancer 79(5/6): 888-894, 1999
Heyl W, Wolff JM, Biesterfeld S, Schroder W, Zitzelsberger D, Jakse G, Rath W: Immunohistochemical analysis of prostatespecific antigen does not correlate to other prognostic factors in breast cancer. Anticancer Res 19: 2563-2566, 1999
Yu H, Levesque MA, Clark GM, Diamandis EP: Enhanced prediction of breast cancer prognosis by evaluating expression of p53 and prostate-specific antigen in combination. Br J Cancer 81(3): 490-495, 1999
Wick MR, Lillemoe TJ, Copland GT, Swanson PE, Manivel JC, Kiang DT: Gross cystic disease fluid protein-15 as a marker for breast cancer. Hum Pathol 20: 281-287, 1989
Elston CW, Ellis IO: Pathologic prognostic factors in breast cancer. I. The value of histologic grade in breast cancer: experience from a large study with long-term followup. Histopathol 19: 403-410, 1991
Holland R, Peterse JL, Millis RR, Eusebi V, Faverly D, van de Vijver MJ, Zafrani B: Ductal carcinoma in situ: A Proposal for a new classification. Sem Diag Pathol 11: 167-180, 1994
Hall RE, Clements JA, Birrell SN, Tilley WD: Prostatespecific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br J Cancer 78(3): 360-365, 1998
Bodey B, Bodey B Jr, Kaiser HE: Immunocytochemical detection of prostate specific antigen expression in human breast carcinoma cells. Anticancer Res 17: 2577-2582, 1997
Howarth DJC, Aronson IB, Diamandis EP: Immunohistochemical localization of prostate-specific antigen in benign and malignant breast tissues. Br J Cancer 75: 1646-1651, 1997
Yu H, Levesque MA, Clark GM, Diamandis EP: Prognostic value of prostate-specific antigen for women with breast cancer: a large united states cohort study. Clin Cancer Res 4: 1489-1497, 1998
Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R, Sismondi P: Prostatespecific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104-2110, 1995
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miller, M.K., Unger, P.D. & Bleiweiss, I.J. Immunohistochemical analysis of prostate specific antigen in breast cancer*. Breast Cancer Res Treat 68, 111–116 (2001). https://doi.org/10.1023/A:1011959127928
Issue Date:
DOI: https://doi.org/10.1023/A:1011959127928